FindTrial
Sign In

TO EVALUATE THE EFFCT OF ORAL IVABRADINE FOR ATTENUATION OF HEMODYNAMIC FOLLOWING LARYNGOSCOPY AND INTUBATION IN PATIENT UNDERGOING ELECTIVE SURGERY UNDER GENERAL ANAESTHESIA

Use of Ivabradine for Attenuation of Stressor Response following Laryngoscopy and Intubation in patient undergoing surgery under general anaesthesia in tertiary care hospital: a double blind placebo controlled randomized trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/046943
Enrollment
60
Registered
2022-11-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: USE OF IVABRADINE FOR ATTENUATION OF HEMODYNAMIC STATUS FOLLOWING LARYNGOSCOPY AND INTUBATION.: GROUP I WILL RECIEVE 5 MG IVABRADINE ONE HOUR BEFORE INDUCTION OF ANAESTHESIA AND HEMODY

Sponsors

SIKKIM MANIPAL INSTITUTE OF MEDICAL SCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All American Society of Anaesthesiology (ASA) physical status I, aged 18- 50 yrs posted for elective non cardiac surgery under general anaesthesia requiring endotracheal intubation who consent to be part of the study

Exclusion criteria

Exclusion criteria: 1. Patient not giving consent for the study. 2. ASA status >II 6 3. Anticipated difficult intubation(Mallampati Class III and IV, thyromental height < 6 cm , inter-incisor distance <3cm and cervical instability. 4. Baseline heart rate < 60 b/min or >90 b/min 5. Baseline BP <90/50mm Hg (65) or >140/85mm Hg (105) 6. History of syncope, palpitation, chest pain or cardiac/ respiratory illness, liver or renal dysfunction. 7. History of substance abuse. 8. Those with ECG abnormalities.

Design outcomes

Primary

MeasureTime frame
the change in heart rate, blood pressure and MAP (mean arterial pressure) following laryngoscopy and intubation, which shall be compared between the study and control group. Unattenuated these changes can be 20% or more.Timepoint: 24 hours of total study duration in each case starting from the oral intake of study drug.—

Secondary

MeasureTime frame
To assess incidence of side effects and complication if any due to study drugTimepoint: 24 hrs in postoperative period after intake of study drug—

Countries

India

Contacts

Public ContactTETIKCHA GURUNG

SIKKIM MANIPAL INSTITUTE OF MEDICAL SCIENCES

basantakumar.g@smims.smu.edu.in9831779215

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026